Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia

Key Points

• This research aims to investigate the relationship between the overuse of thrombopoietin receptor agonists and myelofibrosis in pediatric patients with immune thrombocytopenia.
• Evaluated pediatric patients with immune thrombocytopenia receiving thrombopoietin receptor agonists.
• Monitored patient responses to treatment and incidents of myelofibrosis.
• Conducted a retrospective analysis of patient records.
• Increased usage of thrombopoietin receptor agonists correlated with higher rates of myelofibrosis.
• Patients with suboptimal treatment responses showed a significantly higher incidence of myelofibrosis.
• Findings suggest a need for reevaluating treatment strategies in pediatric immune thrombocytopenia.